
Join to view full profile
200 Hawkins DrDept of OphthalmologyIowa City, IA 52242
Phone+1 319-356-3185
Fax+1 319-356-0363
Dr. Sohn is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Elliott Sohn is an ophthalmologist based in Iowa City, IA, specializing in retinal diseases. He completed his medical degree and residency at the University of Washington, followed by a medical retina fellowship at Moorfields Eye Hospital in London, UK, and vitreoretinal fellowship at Doheny Eye Institute / University of Southern California. Dr. Sohn is a tenured Professor, Endowed Chair in Diabetic Retinopathy Research, and attending physician at the University of Iowa, with prior roles including associate professor and director of retina fellowships. His expertise includes diabetes mellitus, diabetic retinopathy, macular degeneration, macular holes, retinal detachments, and epiretinal membranes. He has authored >100 publications related to retinal conditions and serves as the principal investigator in clinical trials. He runs an NIH-funded research lab focusing on AI, immunology, and genetics to reduce and prevent blindness in age-related macular degeneration and diabetes.
Education & Training
University of WashingtonResidency, Ophthalmology, 2004 - 2007
University of WashingtonInternship, Internal Medicine, 2003 - 2004
University of Washington School of MedicineClass of 2003
Certifications & Licensure
IA State Medical License 2010 - 2026
CA State Medical License 2008 - 2010
WA State Medical License 2003 - 2007
American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2017
- CMS Meaningful Use Stage 2 Certification Outgoing Public Health Reporting from EpicCare Functionality, Epic Systems Corporation, 2012-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2017
Clinical Trials
- MMP-9 Inhibition for Recalcitrant Wet AMD Start of enrollment: 2020 Nov 04
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- SURGICAL MANAGEMENT AND OUTCOMES OF LARGE HIGH MYOPIC MACULAR HOLES: Global Macular Hole Multicenter Study 3.Tianyu Liu, Nassim A Abreu-Arbaje, Joana Andoh, J Fernando Arevalo, Remzi Avci
Retina. 2026-08-01 - Progressive Expansion of Chorioretinal Atrophy in Placoid-Spectrum Disease.Timothy M Boyce, Elliott H Sohn, Jonathan F Russell, Ian C Han
Ocular Immunology and Inflammation. 2026-07-01 - MMP9 Genotype and Systemic T-Cell Subsets Correlate With Structural and Functional Outcomes in Neovascular Age-Related Macular Degeneration.Thomas L Martinez, Zeb R Zacharias, Kyungmoo Lee, Ian C Han, Chunhua Jiao
Investigative Ophthalmology & Visual Science. 2026-06-01
Grant Support
- MMP-9 based immune-driven mechanisms of neovascular AMDUNIVERSITY OF IOWA2023–2027
- MMP-9 based immune-driven mechanisms of neovascular AMDUNIVERSITY OF IOWA2023–2027
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









